Literature DB >> 22197477

Neural circuits underlying the pathophysiology of mood disorders.

Joseph L Price1, Wayne C Drevets.   

Abstract

Although mood disorders constitute leading causes of disability, until recently little was known about their pathogenesis. The delineation of anatomical networks that support emotional behavior (mainly derived from animal studies) and the development of neuroimaging technologies that allow in vivo characterization of anatomy, physiology, and neurochemistry in human subjects with mood disorders have enabled significant advances towards elucidating the pathophysiology of major depressive disorder (MDD) and bipolar disorder (BD). In this review, we integrate insights from human and animal studies, which collectively suggest that MDD and BD involve dysfunction within an extended network including the medial prefrontal cortex and anatomically-related limbic, striatal, thalamic and basal forebrain structures.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22197477     DOI: 10.1016/j.tics.2011.12.011

Source DB:  PubMed          Journal:  Trends Cogn Sci        ISSN: 1364-6613            Impact factor:   20.229


  295 in total

1.  Morphological changes in subregions of hippocampus and amygdala in major depressive disorder patients.

Authors:  Zhijun Yao; Yu Fu; Jianfeng Wu; Wenwen Zhang; Yue Yu; Zicheng Zhang; Xia Wu; Yalin Wang; Bin Hu
Journal:  Brain Imaging Behav       Date:  2020-06       Impact factor: 3.978

2.  Frontal theta cordance predicts 6-month antidepressant response to subcallosal cingulate deep brain stimulation for treatment-resistant depression: a pilot study.

Authors:  James M Broadway; Paul E Holtzheimer; Matthew R Hilimire; Nathan A Parks; Jordan E Devylder; Helen S Mayberg; Paul M Corballis
Journal:  Neuropsychopharmacology       Date:  2012-03-14       Impact factor: 7.853

3.  Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression.

Authors:  Marta Peciña; Amy S B Bohnert; Magdalena Sikora; Erich T Avery; Scott A Langenecker; Brian J Mickey; Jon-Kar Zubieta
Journal:  JAMA Psychiatry       Date:  2015-11       Impact factor: 21.596

4.  Neural signatures of experimentally induced flow experiences identified in a typical fMRI block design with BOLD imaging.

Authors:  Martin Ulrich; Johannes Keller; Georg Grön
Journal:  Soc Cogn Affect Neurosci       Date:  2015-10-26       Impact factor: 3.436

5.  Brain areas associated with resilience to depression in high-risk young women.

Authors:  Birce Begum Burhanoglu; Gulsah Dinçer; Alpaslan Yilmaz; Ozgun Ozalay; Ozgul Uslu; Esmin Unaran; Omer Kitis; Ali Saffet Gonul
Journal:  Brain Struct Funct       Date:  2021-01-17       Impact factor: 3.270

Review 6.  Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression.

Authors:  P Licznerski; R S Duman
Journal:  Neuroscience       Date:  2012-10-02       Impact factor: 3.590

7.  Reduced connexin 43 immunolabeling in the orbitofrontal cortex in alcohol dependence and depression.

Authors:  José Javier Miguel-Hidalgo; Barbara A Wilson; Syed Hussain; Ashish Meshram; Grazyna Rajkowska; Craig A Stockmeier
Journal:  J Psychiatr Res       Date:  2014-04-16       Impact factor: 4.791

8.  Increased neural activity during overt and continuous semantic verbal fluency in major depression: mainly a failure to deactivate.

Authors:  Heidelore Backes; Bruno Dietsche; Arne Nagels; Mirjam Stratmann; Carsten Konrad; Tilo Kircher; Axel Krug
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-02-21       Impact factor: 5.270

9.  Tracking mood fluctuations with functional network patterns.

Authors:  Nykan Mirchi; Richard F Betzel; Boris C Bernhardt; Alain Dagher; Bratislav Mišic
Journal:  Soc Cogn Affect Neurosci       Date:  2019-01-04       Impact factor: 3.436

Review 10.  The organization of the stress system and its dysregulation in depressive illness.

Authors:  P W Gold
Journal:  Mol Psychiatry       Date:  2014-12-09       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.